DGAP-News

PharmaSGP publishes H1 Report 2020 and confirms strong performance and positive outlook for the full year - Seite 2

The consistent implementation of the strategy is also reflected in the significant rise in revenues of the product category "Health Brands", which increased by € 5.1 million to € 28.6 million in the first half of the year. In the German-speaking countries, the product category that is the main focus of PharmaSGP's product strategy increased by 20.3%, in the rest of Europe by 29.9%. As expected, revenues in the product category "Beauty Brands" declined by € 2.4 million to € 5.2 million (H1 2019: € 7.6 million).

Adjusted^[1] earnings before interest and taxes (EBIT) increased disproportionately to revenues by 17.7% to € 10.6 million (H1 2019: € 9.0 million). The adjusted EBIT margin thus increased to 31.5% (H1 2019: 28.7%). Unadjusted EBIT amounted to € 9.5 million and corresponds to an unadjusted EBIT margin of 28.2%.

Natalie Weigand, CEO of PharmaSGP: "We are extremely satisfied with our strong business performance in the first half of 2020. We have been very successful in further developing our product portfolio through line extensions, entering into new indication areas and further expanding the international markets. With a total of seven product launches, we even exceeded the planned number of new products in the first half of the year. In particular, we have significantly strengthened the 'Health Brands', which are the main focus of our product strategy."

As a pure-play consumer health company with a clear focus on end consumers, a flexible D2C marketing approach and a very dynamic portfolio development, PharmaSGP has a clear competitive advantage. According to the strategy consultancy Sempora Consulting, the strengths of the business model became particularly evident during the market changes caused by the corona pandemic in the first half of 2020. In a performance comparison between close to 50 competitors on how they developed during the first half of the year, PharmaSGP ranked first by far.

In view of its good market positioning, PharmaSGP has many highly attractive growth opportunities - both organic and inorganic. In order to be able to exploit these opportunities even more consistently, both nationally and internationally, PharmaSGP has increased its management capacity by appointing Maria-Johanna Schaecher (55) Chief Business Development Officer (CBDO). Since September 16, 2020, Mrs. Schaecher is driving forward the implementation of the growth strategy together with CEO Natalie Weigand and CFO Michael Rudolf. Previously, Mrs. Schaecher held many top management positions in the healthcare, biotech and pharmaceutical industries and among others has significant operational experience in M&A and international expansion.